Androgen-deprivation therapy (ADT) is the mainstay treatment for newly diagnosed advanced PCa and recurrence after radical therapy, owing to the lineage-specific dependence on androgen receptor (AR) signaling at all stages of PCa progression 2. The gene discussed is AR; the disease is posterior cortical atrophy.